Cell lines are created from patient-derived blood and tumor tissue. Our cell platforms are developed from the same patient and were HLA-typed to ensure they are from the same patient.
What are the advantages of HLA-matched T cell and Tumor Cell Lines?
How do we offer these platforms?
What can we study using these cell lines?
There are several studies that can help our partners evaluate phenotypic and functional analysis across various assay formats. The well-characterized nature of our cell platforms enables us to understand the “inputs” and “outputs” in the screening of drug candidates.
- T cell Assays
- Immunogenicity Testing
- Biochemical Testing
- Immune Cell Activation and Inhibition
- Mechanistic Assays
- Tumor killing assays
- Tumor cell assays
- Natural killer cell assays
- Macrophage and Dendritic cell assays
- Neutrophil assays
- Fibroblast assays
- Cytokine release assays
- T cell mediated Exhaustion assay
- T cell mediated Chemotaxis assays
- T cell mediated cytoxicity assay
- ADA screening
- Titration and Isotyping
- Neutralizing Ab
- Binding
- Blocking
- Affinity
- T cell Dependent Antibody Response (TDAR)
- Tetanus Toxoid Recall Assay – proliferation
- Flu antigen Recall – Antigen Response
- CMV/EBV/Flu – Increase TNF
- Mixed Lymphocyte Reaction (MLR) Assays
- Mart-1 (melanoma antigen)
- Immunophenotyping in blood or organs
- Compliment Assays
- Antibody Dependent Cell Cytotoxicity (ADCC)
- Cell Dependent Cytoxicity (CDC)
- Receptor Occupancy
- Neutrophil/Macrophage
- Oxidative Burst
- Phagocytosis
- Migration
- Th1/Th17 Differentiation assays
- Tumor Associated Macrophages (TAM)
- Regulatory T cells (Tregs) Suppression assay
- M1/M2 Macrophage assays
This is a PD-L1 sensitive tumor line
TIM-3, PD-1, CD25, CD80, HVEM, GITR, CD73, PD-L2, OX-40L, CD155, CD112, CD44, CD49a (α1 integrin), CD49b (α2 integrin), CD29 (β1 integrin), CD95 (FAS) CD54 (ICAM-1), CD11a (LFA-1a)
CTL and Tumor 001 was derived from a colon cancer patient. This HLA-matched pairing is PD-L1 sensitive.
Tumor 001
PD-L1, HVEM, OX-40L, CD155, CD112, CD44,
CD49b(α2 integrin), CD29(β1 integrin), CD95 (FAS)
Chemokines and Chemokine Receptors
CCR2,CCR3, CCL15,CCL2,CCL3,CCL4,CXCL11, CCL19,CCL21, CCL25, and CXCL9
Example studies:
- Cytotoxity (CTL) studies
- Immunosuppression assays to evaluate the role of Tregs and Tumro Associated Macrophages (TAMs) on CTL proliferation and apoptosis of matched tumor
- Blocking and binding studies of known cell surface targets
This is a PD-1 sensitive tumor line
CTL and Tumor 002 derived from a female colon cancer patient at time of surgery. This HLA-matched cell pairing is PD-1 sensitive.
PD-1, TIGIT, OX-40, 4-1BB, CD80, CD44, CD95 CD29(β1 integrin), CD3, TCR α/β, CD95 (FAS), CD54 (ICAM-1), CD11a (LFA-1a)
Tumor 002
PD-L1, HVEM, OX-40L, CD155, CD112, CD44 CD49a (α1 integrin), CD49b (α2 integrin), CD29 (β1 integrin), CD95 (FAS)
Chemokines and Chemokine Receptors
CCR2,CCR3, CCL15,CCL2,CCL3,CCL4,CXCL11, CCL19,CCL21, CCL25, and CXCL9
Example studies:
- Cytotoxity (CTL) studies
- Immunosuppression assays to evaluate the role of Tregs and Tumro Associated Macrophages (TAMs) on CTL proliferation and apoptosis of matched tumor
- Chemokine blocking studies of SDF1α and CXCR4
- Blocking and binding studies of known cell surface targets
This is a PD-1 sensitive tumor line
CTL and Tumor 003 derived from a melanoma male Caucasian patient. This HLA-matched cell pairing is PD-1 and PD-L1 sensitive.
TIM-3, PD-1, 4-1BB, ICOS, CD8, CD25, CD44
CD95 (FAS),CD80(B7-1), CD29(β1 integrin), CD49b (α2 integrin), CD54 (ICAM-1), CD11a (LFA-1A)
Tumor 003
PD-L1, CD44, ICOSL, 4-1BBL, PD-L2, CD112, HVEM, CD49a (α1 integrin), CD49b (α2 integrin), CD29 (β1 integrin), CD95 (FAS)
Chemokines and Chemokine Receptors
CCR7,CCR9, CXCR3,CXCR1, CCL21,CCL25, CXCL12,CXCL19 and CXCL9
Example studies:
- Cytotoxity (CTL) studies
- Immunosuppression assays to evaluate the role of Tumro Associated Macrophages (TAMs) on CTL proliferation and apoptosis of matched tumor
- Chemokine blocking studies of SDF1α and CXCR4 and affects on CTL migration
- Blocking and binding studies of known cell surface targets